Selective lack of the C16:0 fatty acid isoform of sulfatide in pancreas of type II diabetic animal models

APMIS

Volumn 111, Issue 9, 2003, Pages 867-877

  Blomqvist, Maria ^a   Osterbye, Thomas ^b   Månsson, Jan Eric ^a   Horn, Thomas ^c   Buschard, Karsten ^b   Fredman, Pam ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b Kommunehospitalet ^*  (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Animal model; Glycosphingolipid; Insulin crystals; Sulfatide; Type II diabetes

Indexed keywords

GLYCOSPHINGOLIPID; INSULIN; SULFATIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY LABELING; ARTICLE; CELL ACTIVITY; CELL ISOLATION; CELL LABELING; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC PREDISPOSITION; HEREDITY; LIPID METABOLISM; LIPOGENESIS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT; RAT STRAIN; SECRETORY CELL; SECRETORY GRANULE; THIN LAYER CHROMATOGRAPHY;

ANIMALS; BREFELDIN A; CHLOROQUINE; CHROMATOGRAPHY, THIN LAYER; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY ACIDS; FUMONISINS; GALACTOSYLCERAMIDES; HUMANS; ISLETS OF LANGERHANS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, OBESE; MICROSCOPY, ELECTRON; PROTEIN ISOFORMS; PROTEIN SYNTHESIS INHIBITORS; RATS; RATS, INBRED LEW; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SULFOGLYCOSPHINGOLIPIDS;

EID: 0141484445     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0463.2003.1110905.x     Document Type: Article

References (42)

1. Buschard K, Josefsen K, Horn T, Larsen S, Fredman P. Sulphatide antigen in islets of Langerhans and in diabetic glomeruli, and anti-sulphatide antibodies in type 1 diabetes mellitus. APMIS 1993;101:963-70.
2. Hsu FF, Bohrer A, Turk J. Electrospray ionization tandem mass spectrometric analysis of sulfatide. Determination of fragmentation patterns and characterization of molecular species expressed in brain and in pancreatic islets. Biochim Biophys Acta 1998;1392:202-16.
3. Fredman P, Månsson JE, Rynmark BM, Josefsen K, Ekblond A, Halldner L, et al. The glycosphingolipid sulfatide in the islets of Langerhans in rat pancreas is processed through recycling; possible involvement in insulin trafficking. Glycobiology 2000;10:39-50.
4. Vos JP, Lopes-Cardozo M, Gadella BM. Metabolic and functional aspects of sulfogalactolipids. Biochim Biophys Acta 1994;1211:125-49.
5. Ishizuka I. Chemistry and functional distribution of sulfoglycolipids. Prog Lipid Res 1997;36:245-319.
6. Orci L. The insulin cell: its cellular environment and how it processes (pro)insulin. Diabetes Metab Rev 1986;2:71-106.
7. Halban PA, Wollheim CB. Intracellular degradation of insulin stores by rat pancreatic islets in vitro. An alternative pathway for homeostasis of pancreatic insulin content. J Biol Chem 1980;255:6003-6.
8. Osterbye T, Jorgensen KH, Fredman P, Tranum-Jensen J, Kaas A, Brange J, et al. Sulfatide promotes the folding of proinsulin, preserves insulin crystals, and mediates its monomerization. Glycobiology 2001;11:473-9.
9. Buschard K, Hoy M, Bokvist K, Olsen HL, Madsbad S, Fredman P, et al. Sulfatide controls insulin secretion by modulation of ATP-sensitive K(+) -channel activity and Ca(2+)-dependent exocytosis in rat pancreatic beta-cells. Diabetes 2002;51:2514-21.
10. Herberg L, Coleman DL. Laboratory animals exhibiting obesity and diabetes syndromes. Metabolism 1977;26:59-99.
11. Coleman DL. Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice. Diabetologia 1978;14:141-8.
12. Rosengren B, Fredman P, Månsson JE, Svennerholm L. Lysosulfatide (galactosylsphingosine-3-O-sulfate) from metachromatic leukodystrophy and normal human brain. J Neurochem 1989;52:1035-41.
13. Svennerholm L, Hakansson G, Månsson JE, Vanier MT. The assay of sphingolipid hydrolases in white blood cells with labelled natural substrates. Clin Chim Acta 1979;92:53-64.
14. Karlsson G, Månsson JE, Wikstrand C, Bigner D, Svennerholm L. Characterization of the binding epitope of the monoclonal antibody DMAb-1 to ganglioside GM2. Biochim Biophys Acta 1990;1043:267-72.
15. Fredman P, Mattsson L, Andersson K, Davidsson P, Ishizuka I, Jeansson S, et al. Characterization of the binding epitope of a monoclonal antibody to sulphatide. Biochem J 1988;251:17-22.
16. Koshy KM, Boggs JM. A high yield saponification galactosylceramide 3-sulfate. Lipids 1982;17:998-1000.
17. Kopasczyk KC, Radin NS. In vivo conversions of cerebroside and ceramide in rat brain. J Lipid Res 1965;6:140-5.
18. Buschard K, Aaen K, Horn T, Van Damme J, Bendtzen K. Interleukin 6: a functional and structural in vitro modulator of beta- cells from islets of Langerhans. Autoimmunity 1990;5:185-94.
19. Svennerholm L, Fredman P. A procedure for the quantitative isolation of brain gangliosides. Biochim Biophys Acta 1980;617:97-109.
20. Davidsson P, Fredman P, Månsson JE, Svennerholm L. Determination of gangliosides and sulfatide in human cerebrospinal fluid with a microimmunoaffinity technique. Clin Chim Acta 1991;197:105-15.
21. Pernber Z, Molander-Melin M, Berthold CH, Hansson E, Fredman P. Expression of the myelin and oligodendrocyte progenitor marker - sulfatide - in neurons and astrocytes of adult rat brain. J Neurosci Res 2002;69:86-93.
22. Blomqvist M, Kaas A, Månsson JE, Formby B, Rynmark BM, Buschard K, et al. Developmental expression of the type I diabetes related antigen sulfatide and sulfated lactosylceramide in mammalian pancreas. J Cell Biochem 2003;89:301-10.
23. Schlichtkrull J. Insulin crystals. PhD thesis, University of Copenhagen, Munksgaard, Copenhagen, 1961.
24. Merrill AH Jr, Schmelz EM, Dillehay DL, Spiegel S, Shayman JA, Schroeder JJ, et al. Sphingolipids - the enigmatic lipid class: biochemistry, physiology, and pathophysiology. Toxicol Appl Pharmacol 1997;142:208-25.
25. Klausner RD, Donaldson JG, Lippincott-Schwartz J, Brefeldin A. Insights into the control of membrane traffic and organelle structure. J Cell Biol 1992;116:1071-80.
26. de Duve C, de Barsy T, Poole B, Trouet A, Tulkens P, Van Hoof F. Lysosomotropic agents. Biochem Pharmacol 1974;23:2495-531.
27. Buschard K, Josefsen K, Hansen SV, Horn T, Marshall MO, Persson H, et al. Sulphatide in islets of Langerhans and in organs affected in diabetic late complications: a study in human and animal tissue. Diabetologia 1994;37:1000-6.
28. Buschard K, Josefsen K, Rygaard J, Spitalnik SL. Pancreatic islet-cell epitope recognized by an anti-sulphatide monoclonal antibody. APMIS 1991;99:1151-6.
29. DeFronzo RA, Binder C, Wahren J, Felig P, Ferrannini E, Faber OK. Sensitivity of insulin secretion to feedback inhibition by hyperinsulinaemia. Acta Endocrinol (Copenh) 1981;98:81-6.
30. Buschard K, Schloot NC, Kaas A, Bock T, Horn T, Fredman P, et al. Inhibition of insulin-specific autoreactive T-cells by sulphatide which is variably expressed in beta cells. Diabetologia 1999;42:1212-8.
31. Tjälve H, Olsson S, Andersson A. The uptake of 14C-chloroquine by mouse pancreatic islets in vitro. Acta Pharmacol Toxicol (Copenh) 1980;47:38-44.
32. Hallberg A, Berne C, Andersson A. Effects of chloroquine on lipid metabolism of mouse pancreatic islets. Biochem Pharmacol 1984;33:1465-70.
33. Andersson A, Olsson S, Tjälve H. Chloroquine inhibits the insulin production of isolated pancreatic islets. Biochem Pharmacol 1980;29:1729-35.
34. Hummel KP, Coleman DL, Lane PW. The influence of genetic background on expression of mutations at the diabetes locus in the mouse. I. C57BL-KsJ and C57BL-6J strains. Biochem Genet 1972;7:1-13.
35. Coleman DL, Hummel KP. The influence of genetic background on the expression of the obese (Ob) gene in the mouse. Diabetologia 1973;9:287-93.
36. Coleman DL. Lessons from studies with genetic forms of diabetes in the mouse. Metabolism 1983;32:162-4.
37. Rosenberg A, Stern N. Changes in sphingosine and fatty acid components of the gangliosides in developing rat and human brain. J Lipid Res 1966;7:122-31.
38. Kannagi R, Nudelman E, Hakomori S. Possible role of ceramide in defining structure and function of membrane glycolipids. Proc Natl Acad Sci U S A 1982;79:3470-4.
39. Kannagi R, Stroup R, Cochran NA, Urdal DL, Young WW Jr, Hakomori S. Factors affecting expression of glycolipid tumor antigens: influence of ceramide composition and coexisting glycolipid on the antigenicity of gangliotriaosyl-ceramide in murine lymphoma cells. Cancer Res 1983;43:4997-5005.
40. Ladisch S, Sweeley CC, Becker H, Gage D. Aberrant fatty acyl alpha-hydroxylation in human neuroblastoma tumor gangliosides. J Biol Chem 1989;264:12097-105.
41. Lingwood CA. Aglycone modulation of glycolipid receptor function. Glycoconj J 1996;13:495-503.
42. Mamelak D, Mylvaganam M, Whetstone H, Hartmann E, Lennarz W, Wyrick PB, et al. Hsp70s contain a specific sulfogalactolipid binding site. Differential aglycone influence on sulfogalactosyl ceramide binding by recombinant prokaryotic and eukaryotic hsp70 family members. Biochemistry 2001;40:3572-82.